Based upon discussion, the panel consensus was to revise the systemic therapies list as follows:

### Preoperative Chemoradiation

- **Preferred Regimens**
  - Paclitaxel and carboplatin (category 1)  
  - Cisplatin and fluorouracil (category 1)  
  - Oxaliplatin and fluorouracil (changed from category 2A to a category 1 recommendation)  
  - Cisplatin and capecitabine  
  - Oxaliplatin and capecitabine

- **Other Regimens**
  - Irinotecan and cisplatin (category 2B)  
  - Docetaxel or paclitaxel and fluoropyrimidine (category 2B)

- The following combinations were removed:
  - Paclitaxel and cisplatin  
  - Carboplatin and fluorouracil  
  - Oxaliplatin, docetaxel, and capecitabine

### Perioperative Chemotherapy

- Fluorouracil and cisplatin (category 1) was added

### Postoperative Chemotherapy

- Capecitabine and cisplatin was added

---

References:

For the preoperative chemoradiation, perioperative chemotherapy, and postoperative chemotherapy references, see the NCCN 1.2013 Guidelines for Gastric cancer (www.nccn.org)


GAST-E (2 of 13) (continued)

**Internal request:**
Suggestion was made to review and revise the systemic therapy regimens used for the treatment of gastric cancer.

**Panel Discussion**
Based upon discussion, the panel consensus was to revise the systemic therapies as follows:

**Sequential Chemotherapy and Chemoradiation**
- This section and the following combinations were removed:
  - Irinotecan and cisplatin
  - Paclitaxel and cisplatin
  - Docetaxel and cisplatin
  - 5-fluorouracil and cisplatin; 5-fluorouracil and paclitaxel

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>Vote</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAST-E (2 of 13) (continued) Internal request: Suggestion was made to review and revise the systemic therapy regimens used for the treatment of gastric cancer.</td>
<td>Based upon discussion, the panel consensus was to revise the systemic therapies as follows: <strong>Sequential Chemotherapy and Chemoradiation</strong> - This section and the following combinations were removed: - Irinotecan and cisplatin - Paclitaxel and cisplatin - Docetaxel and cisplatin - 5-fluorouracil and cisplatin; 5-fluorouracil and paclitaxel</td>
<td>YES</td>
<td>NO</td>
</tr>
</tbody>
</table>
Based upon discussion, the panel consensus was to revise the first-line systemic therapies for metastatic or locally advanced cancer as follows:

**First-line Therapy**

- **Preferred Regimens**
  - DCF (docetaxel, cisplatin and fluorouracil) (category 1)
    - Docetaxel, oxaliplatin and fluorouracil
    - Docetaxel, carboplatin and fluorouracil (category 2B)
  - ECF (epirubicin, cisplatin and fluorouracil) (category 1)
    - Epirubicin, oxaliplatin and fluorouracil
    - Epirubicin, cisplatin and capecitabine
    - Epirubicin, oxaliplatin and capecitabine
  - Fluoropyrimidine (fluorouracil or capecitabine) and cisplatin (category 1)
  - Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin
  - Fluorouracil and irinotecan

- **Other Regimens**
  - Paclitaxel with cisplatin or carboplatin
  - Docetaxel with cisplatin
  - Docetaxel and irinotecan (category 2B)
  - Fluoropyrimidine (fluorouracil or capecitabine)

For the first-line therapy references, see the NCCN 1.2013 Guidelines for Gastric Cancer ([www.nccn.org](http://www.nccn.org))
Based upon discussion, the panel consensus was to revise the second-line therapies and alternative regimens for metastatic or locally advanced cancer as follows:

**Second-line Therapy**

- **Preferred Regimens**
  - Docetaxel (category 2B)
  - Paclitaxel (category 2B)
  - Irinotecan (category 2B)
- **Other Regimens**
  - Irinotecan and cisplatin
  - Irinotecan and fluoropyrimidine (fluorouracil or capecitabine) (category 2B)
  - Docetaxel and irinotecan (category 2B)
- **The following combinations were removed:**
  - Irinotecan and mitomycin

**Alternative regimens for consideration (these may be combined with other regimens when appropriate)**

- The following combinations were removed:
  - Gemcitabine, fluorouracil, and leucovorin
  - Mitomycin, cisplatin, and fluorouracil
  - Pegylated liposomal doxorubicin, cisplatin and fluorouracil
  - Erlotinib

---

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>Vote</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GAST-E (3 of 13)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Internal request:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suggestion was made to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>review and revise the</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>systemic therapy regimens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>used for the treatment of</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gastric cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For the second-line therapy and alternative regimens references, see the NCCN 1.2013 Guidelines for Gastric cancer ([www.nccn.org](http://www.nccn.org))